rusfertide

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

News

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

FDA clears Takeda, Protagonist's first-in-class PV drug

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Takeda scores with polycythemia vera drug in phase 3 trial

Takeda grabs late-stage haematology drug from Protagonist

Closing the global evidence gap in oncology, with Flatiron H...

Securing your ROI: Turning post-acquisition integration into...

rusfertide

Editor's Picks